Neumora Therapeutics, INC

Neumora Therapeutics announced favorable pre-clinical toxicology results for its obesity and cardiometabolic disease drug candidate, NMRA-215, with plans for clinical advancement.

Neumora Therapeutics announced the discontinuation of its navacaprant development program after Phase 3 studies failed to meet primary endpoints, while advancing other pipeline candidates.

Neumora Therapeutics stockholders re-elected three directors and ratified the appointment of Ernst & Young LLP as auditors.

Neumora Therapeutics reported Q1 2026 financial results, highlighting strong cash position and progress across key clinical programs, with several data readouts expected in H2 2026.

Neumora reported Q4 and full-year 2025 results, highlighted new NMRA-511 Alzheimer’s agitation data, full enrollment of KOASTAL-2/-3 with Q2 2026 readouts, selected NMRA-898 for schizophrenia, and pushed NMRA-215 to Q1 2027 amid rat tox retest.

Neumora Therapeutics presents positive Phase 1b data for NMRA-511, demonstrating strong efficacy and favorable tolerability in Alzheimer's disease agitation, particularly in patients with elevated anxiety.

Neumora Therapeutics reported continued net losses in Q3 2025, a significant reduction in cash, and a major setback with its lead candidate navacaprant failing its Phase 3 primary endpoint.

Neumora Therapeutics reports an increased net loss and higher cash burn for the first half of 2025, securing a new $125 million term loan to extend its operational runway amidst ongoing clinical trials and a class action lawsuit.

Neumora Therapeutics announces its Q1 2025 financial results, detailing operating expenses, liquidity, and progress in its clinical development programs, including navacaprant and NMRA-511.

Neumora Therapeutics reports a net loss of $72.5 million for the third quarter of 2024, with ongoing clinical trials and research and development activities.

Neumora Therapeutics, a clinical-stage biopharmaceutical company, released its second quarter 2024 financial results, highlighting ongoing clinical trials and financial position.

Neumora Therapeutics reports a net loss of $53.7 million for the first quarter of 2024, while advancing its clinical programs, including the Phase 3 KOASTAL program for navacaprant.

Neumora outlined multiple 2026 readouts, detailed loan and ATM financing activity, and reported a $236.9M 2025 net loss with $182.5M in year-end cash as it advances MDD, Alzheimer’s agitation, schizophrenia and obesity programs.

Neumora Therapeutics' 10-K filing summarizes the company's financial performance for 2024 and provides updates on its clinical-stage neuroscience programs.

Neumora Therapeutics' annual 10-K filing details the company's clinical pipeline progress, financial status, and strategic direction in neuroscience drug development.

Director and major shareholder Kristina Burow received 80,000 stock options with an exercise price of $1.86 as part of her compensation.

Director Matthew K. Fust was granted 80,000 stock options in Neumora Therapeutics, Inc. as part of standard equity compensation.

Neumora Therapeutics director David Piacquad was granted 80,000 stock options as part of standard equity compensation.

Director Alaa Halawa was granted 80,000 stock options in Neumora Therapeutics, Inc. as part of a standard equity compensation arrangement.

Director Maykin Ho was granted 80,000 stock options in Neumora Therapeutics, Inc. as part of a standard equity compensation plan.

Neumora Therapeutics' Chief Operating and Development Officer, Daljit Singh Aurora, sold 6,165 shares of common stock to cover tax withholding obligations.

Neumora Therapeutics has issued its 2026 proxy statement detailing the upcoming annual meeting of stockholders scheduled for May 27, 2026.

Neumora Therapeutics is at risk of being delisted from the Nasdaq Global Select Market due to non-compliance with the minimum bid price requirement.

Neumora Therapeutics announces its 2025 Annual Meeting and seeks stockholder votes on director elections, auditor ratification, stock option repricing, and a potential reverse stock split.

Neumora Therapeutics is asking stockholders to approve the repricing of certain stock options and a reverse stock split at its upcoming annual meeting.

Neumora Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 13, 2024, with proposals including the election of two Class I directors and ratification of Ernst & Young LLP as the independent auditor.

Neumora Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 13, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as the independent auditor.

ARCH Venture Funds and affiliated entities continue to hold a substantial beneficial ownership stake in Neumora Therapeutics, Inc., as detailed in a recent Schedule 13D amendment.

ARCH Venture Fund XII increased its holdings in Neumora Therapeutics, Inc. by purchasing 1.9 million shares for approximately $5 million.

K2 HealthVentures Equity Trust reports a 3.1% beneficial ownership stake in Neumora Therapeutics via debt conversion rights.

A significant Schedule 13G filing reveals Invus entities and Raymond Debbane collectively hold a 4.7% stake in Neumora Therapeutics, Inc. as of March 31, 2026.

Raymond Debbane and affiliated entities, collectively known as the Invus Group, have disclosed a beneficial ownership of 5.4% in Neumora Therapeutics, Inc.

K2 HealthVentures Equity Trust LLC and its managing members have disclosed a 6.6% beneficial ownership in Neumora Therapeutics, Inc. common stock.

FMR LLC and its affiliate Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 2.2% of Neumora Therapeutics Inc.'s common stock as of March 31, 2025.

Paul L. Berns has filed an amended Schedule 13G, disclosing a beneficial ownership of 5.1% in Neumora Therapeutics, Inc. as of December 31, 2024.